Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AENEAS: Aumolertinib vs Gefitinib in EGFR-mutated NSCLC
NCT03849768Phase 3Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03849768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849768.